Conformational changes and translocation of tissue-transglutaminase to the plasma membranes: Role in cancer cell migration

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Kumar, Ambrish ^a   Hu, Jianjun ^b   LaVoie, Holly A ^a   Walsh, Kenneth B ^a   DiPette, Donald J ^a   Singh, Ugra S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b The Department of Mechanical Engineering   (United States)

Author keywords

Cell migration; Invasion; Neuroblastoma; Resveratrol; Tissue transglutaminase

Indexed keywords

CALCIUM ION; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; GUANOSINE TRIPHOSPHATE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RESVERATROL; STILBENE DERIVATIVE; TISSUE TRANSGLUTAMINASE 2, HUMAN;

AMIDATION; ARTICLE; CALCIUM CELL LEVEL; CALCIUM DEPLETION; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CELLULAR DISTRIBUTION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME BINDING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOREACTIVITY; NATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS; NEUROBLASTOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; CALCIUM SIGNALING; CELL MOTION; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PROTEIN CONFORMATION; PROTEIN TRANSPORT; TUMOR CELL LINE;

CALCIUM SIGNALING; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PANCREATIC NEOPLASMS; PROTEIN CONFORMATION; PROTEIN TRANSPORT; STILBENES; TRANSGLUTAMINASES;

EID: 84899973791     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-256     Document Type: Article

References (55)

1. Folk JE, Finlayson JS. The epsilon-(gamma-glutamyl) lysine crosslink and the catalytic role of transglutaminases. Adv Protein Chem 1977, 31:1-133.
2. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003, 4(2):140-156. 10.1038/nrm1014, 12563291.
3. Singh US, Erickson JW, Cerione RA. Identification and biochemical characterization of an 80 kilodalton GTP-binding/transglutaminase from rabbit liver nuclei. Biochemistry 1995, 34(48):15863-15871. 10.1021/bi00048a032, 7495818.
4. Nakaoka H, Perez DM, Baek KJ, Das T, Husain A, Misono K, Im MJ, Graham RM. Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science 1994, 264(5165):1593-1596. 10.1126/science.7911253, 7911253.
5. Begg GE, Carrington L, Stokes PH, Matthews JM, Wouters MA, Husain A, Lorand L, Iismaa SE, Graham RM. Mechanism of allosteric regulation of transglutaminase 2 by GTP. Proc Natl Acad Sci U S A 2006, 103(52):19683-19688. 10.1073/pnas.0609283103, 1750866, 17179049.
6. Telci D, Wang Z, Li X, Verderio EA, Humphries MJ, Baccarini M, Basaga H, Griffin M. Fibronectin-tissue transglutaminase matrix rescues RGD-impaired cell adhesion through syndecan-4 and beta1 integrin co-signaling. J Biol Chem 2008, 283(30):20937-20947. 10.1074/jbc.M801763200, 3258940, 18499669.
7. Collighan RJ, Griffin M. Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids 2009, 36(4):659-670. 10.1007/s00726-008-0190-y, 18982407.
8. Akimov SS, Belkin AM. Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFbeta-dependent matrix deposition. J Cell Sci 2001, 114(Pt 16):2989-3000.
9. Balklava Z, Verderio E, Collighan R, Gross S, Adams J, Griffin M. Analysis of tissue transglutaminase function in the migration of Swiss 3 T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but is important for its secretion. J Biol Chem 2002, 277(19):16567-16575. 10.1074/jbc.M109836200, 11867617.
10. Lin CY, Tsai PH, Kandaswami CC, Chang GD, Cheng CH, Huang CJ, Lee PP, Hwang JJ, Lee MT. Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells. Mol Cancer 2011, 10:87. 10.1186/1476-4598-10-87, 3150327, 21777419.
11. Mehta K, Kumar A, Kim HI. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol 2010, 80(12):1921-1929. 10.1016/j.bcp.2010.06.029, 20599779.
12. Verma A, Wang H, Manavathi B, Fok JY, Mann AP, Kumar R, Mehta K. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 2006, 66(21):10525-10533. 10.1158/0008-5472.CAN-06-2387, 17079475.
13. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 2008, 68(14):5849-5858. 10.1158/0008-5472.CAN-07-6130, 2547344, 18632639.
14. Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, Matei D. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 2007, 67(15):7194-7202. 10.1158/0008-5472.CAN-07-0307, 17671187.
15. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007, 26(17):2459-2470. 10.1038/sj.onc.1210035, 17043648.
16. Fok JY, Ekmekcioglu S, Mehta K. Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 2006, 5(6):1493-1503. 10.1158/1535-7163.MCT-06-0083, 16818508.
17. Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, Bigsby RM, Nakshatri H, Matei D. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 2009, 69(24):9192-9201. 10.1158/0008-5472.CAN-09-1257, 19951993.
18. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 2010, 5(10):e13390. 10.1371/journal.pone.0013390, 2953521, 20967228.
19. Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 2008, 14(8):2476-2483. 10.1158/1078-0432.CCR-07-4529, 18413840.
20. Antonyak MA, Li B, Regan AD, Feng Q, Dusaban SS, Cerione RA. Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem 2009, 284(27):17914-17925. 10.1074/jbc.M109.013037, 2709351, 19403524.
21. Singh US, Pan J, Kao YL, Joshi S, Young KL, Baker KM. Tissue Transglutaminase Mediates Activation of RhoA and MAP Kinase Pathways during Retinoic Acid-induced Neuronal Differentiation of SH-SY5Y Cells. J Biol Chem 2003, 278(1):391-399.
22. Singh US, Kunar MT, Kao YL, Baker KM. Role of transglutaminase II in retinoic acid-induced activation of RhoA- associated kinase-2. EMBO J 2001, 20(10):2413-2423. 10.1093/emboj/20.10.2413, 125450, 11350930.
23. Roy SK, Chen Q, Fu J, Shankar S, Srivastava RK. Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors. PLoS One 2011, 6(9):e25166. 10.1371/journal.pone.0025166, 3181262, 21980390.
24. van Ginkel PR, Sareen D, Subramanian L, Walker Q, Darjatmoko SR, Lindstrom MJ, Kulkarni A, Albert DM, Polans AS. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res 2007, 13(17):5162-5169. 10.1158/1078-0432.CCR-07-0347, 17785572.
25. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila) 2009, 2(5):409-418. 10.1158/1940-6207.CAPR-08-0160, 19401532.
26. Chen Y, Tseng SH, Lai HS, Chen WJ. Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery 2004, 136(1):57-66. 10.1016/j.surg.2004.01.017, 15232540.
27. Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009, 11(11):2851-2897. 10.1089/ars.2008.2412, 19432534.
28. Joshi S, Guleria R, Pan J, DiPette D, Singh US. Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 2006, 25(2):240-247.
29. Kumar A, Singh CK, DiPette DD, Singh US. Ethanol impairs activation of retinoic acid receptors in cerebellar granule cells in a rodent model of fetal alcohol spectrum disorders. Alcohol Clin Exp Res 2010, 34(5):928-937. 10.1111/j.1530-0277.2010.01166.x, 20201933.
30. Kumar A, Singh CK, Lavoie HA, Dipette DJ, Singh US. Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders. Mol Pharmacol 2011, 80(3):446-457. 10.1124/mol.111.071126, 3164333, 21697273.
31. Singh US, Cerione RA. Biochemical effects of retinoic acid on GTP-binding Protein/Transglutaminases in HeLa cells. Stimulation of GTP-binding and transglutaminase activity, membrane association, and phosphatidylinositol lipid turnover. J Biol Chem 1996, 271(44):27292-27298. 10.1074/jbc.271.44.27292, 8910304.
32. Tucholski J, Lesort M, Johnson GV. Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. Neuroscience 2001, 102(2):481-491. 10.1016/S0306-4522(00)00482-6, 11166134.
33. Mishra S, Murphy LJ. Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 2004, 279(23):23863-23868. 10.1074/jbc.M311919200, 15069073.
34. Pinkas DM, Strop P, Brunger AT, Khosla C. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 2007, 5(12):e327. 10.1371/journal.pbio.0050327, 2140088, 18092889.
35. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148(3):421-433. 10.1016/j.cell.2012.01.017, 3431801, 22304913.
36. Mi LY, Ettenson DS, Edelman ER. Phospholipase C-delta extends intercellular signalling range and responses to injury-released growth factors in non-excitable cells. Cell Prolif 2008, 41(4):671-690. 10.1111/j.1365-2184.2008.00544.x, 2838236, 18616695.
37. Padin JF, de Diego AM, Fernandez-Morales JC, Merino C, Maroto M, Calvo-Gallardo E, Arranz JA, Yanez M, Garcia AG. Resveratrol augments nitric oxide generation and causes store calcium release in chromaffin cells. Eur J Pharmacol 2012, 685(1-3):99-107.
38. Stamnaes J, Pinkas DM, Fleckenstein B, Khosla C, Sollid LM. Redox regulation of transglutaminase 2 activity. J Biol Chem 2010, 285(33):25402-25409. 10.1074/jbc.M109.097162, 2919103, 20547769.
39. Kiraly R, Csosz E, Kurtan T, Antus S, Szigeti K, Simon-Vecsei Z, Korponay-Szabo IR, Keresztessy Z, Fesus L. Functional significance of five noncanonical Ca2 + -binding sites of human transglutaminase 2 characterized by site-directed mutagenesis. FEBS J 2009, 276(23):7083-7096. 10.1111/j.1742-4658.2009.07420.x, 19878304.
40. Bergamini CM. GTP modulates calcium binding and cation-induced conformational changes in erythrocyte transglutaminase. FEBS Lett 1988, 239(2):255-258. 10.1016/0014-5793(88)80928-1, 2903073.
41. Kiraly R, Demeny M, Fesus L. Protein transamidation by transglutaminase 2 in cells: a disputed Ca2 + -dependent action of a multifunctional protein. FEBS J 2011, 278(24):4717-4739. 10.1111/j.1742-4658.2011.08345.x, 21902809.
42. Liu S, Cerione RA, Clardy J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci U S A 2002, 99(5):2743-2747. 10.1073/pnas.042454899, 122418, 11867708.
43. Di Venere A, Rossi A, De Matteis F, Rosato N, Agro AF, Mei G. Opposite effects of Ca (2+) and GTP binding on tissue transglutaminase tertiary structure. J Biol Chem 2000, 275(6):3915-3921. 10.1074/jbc.275.6.3915, 10660544.
44. Casadio R, Polverini E, Mariani P, Spinozzi F, Carsughi F, Fontana A, Polverino de Laureto P, Matteucci G, Bergamini CM. The structural basis for the regulation of tissue transglutaminase by calcium ions. Eur J Biochem 1999, 262(3):672-679. 10.1046/j.1432-1327.1999.00437.x, 10411627.
45. Boroughs LK, Antonyak MA, Johnson JL, Cerione RA. A unique role for heat shock protein 70 and its binding partner tissue transglutaminase in cancer cell migration. J Biol Chem 2011, 286(43):37094-37107. 10.1074/jbc.M111.242438, 3199457, 21896482.
46. Lai TS, Davies C, Greenberg CS. Human tissue transglutaminase is inhibited by pharmacologic and chemical acetylation. Protein Sci 2010, 19(2):229-235. 10.1002/pro.301, 2865712, 19998405.
47. Jeong EM, Kim CW, Cho SY, Jang GY, Shin DM, Jeon JH, Kim IG. Degradation of transglutaminase 2 by calcium-mediated ubiquitination responding to high oxidative stress. FEBS Lett 2009, 583(4):648-654. 10.1016/j.febslet.2009.01.032, 19183553.
48. Park D, Choi SS, Ha KS. Transglutaminase 2: a multi-functional protein in multiple subcellular compartments. Amino Acids 2010, 39(3):619-631. 10.1007/s00726-010-0500-z, 20148342.
49. Belkin AM, Tsurupa G, Zemskov E, Veklich Y, Weisel JW, Medved L. Transglutaminase-mediated oligomerization of the fibrin (ogen) alphaC domains promotes integrin-dependent cell adhesion and signaling. Blood 2005, 105(9):3561-3568. 10.1182/blood-2004-10-4089, 1895018, 15637140.
50. Satpathy M, Shao M, Emerson R, Donner DB, Matei D. Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J Biol Chem 2009, 284(23):15390-15399. 10.1074/jbc.M808331200, 2708835, 19324884.
51. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25(1):9-34. 10.1007/s10555-006-7886-9, 16680569.
52. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005, 280(17):17187-17195. 10.1074/jbc.M501250200, 15749705.
53. Wang Z, Griffin M. The role of TG2 in regulating S100A4-mediated mammary tumour cell migration. PLoS One 2013, 8(3):e57017. 10.1371/journal.pone.0057017, 3585722, 23469180.
54. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011, 14(5):612-622. 10.1016/j.cmet.2011.10.002, 3880862, 22055504.
55. Patel KR, Andreadi C, Britton RG, Horner-Glister E, Karmokar A, Sale S, Brown VA, Brenner DE, Singh R, Steward WP, Gescher AJ, Brown K. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med 2013, 5(205):205ra133.